Asthma affects over 34 million Americans and over 300 million people worldwide. A quarter million people die each year from asthma around the world and asthma prevalence is on the rise. Asthma has increased by 75% since 1980, with incidence increasing by 160% in children.
Now, more than ever, research focused on understanding the mechanisms of asthma are needed to help guide the development of tailored treatments.
The Fahy Lab is located in the Cardiovascular Research Institute and the Department of Medicine at the University of California, San Francisco. Our research program aims to uncover disease mechanisms, develop disease biomarkers, and evaluate novel treatments for asthma and other airway diseases. Our program is truly translational, encompassing clinical trials and investigations in patients and studies of disease mechanisms in cell culture and animal model systems.
The Fahy lab's Zesemayat Mekonnen was recently awarded the 2013 ATS Minority Trainee Development Scholarship (MTDS) at the Diversity Forum of the ATS International Conference in Philadelphia. See here for more information.
The Fahy lab has been selected as a center in the Severe Asthma Research Program (SARP) - see program description here. Studies are enrolling now, check out the Airway Clinical Research Center website to participate.
AsthmaNet's VIDA study in adults is enrolling now, check out the Airway Clinical Research Center website to participate.
The Fahy lab has been awarded an NIH Program Project Grant to study "Innate and Adaptive Immune Responses in TH2-High Asthma". This five-year project joins the Airway Clinical Research Center and the Sandler Asthma Basic Research Center for three novel research projects.
The Fahy Lab is affiliated with:
Airway Clinical Research Center ∙ UCSF Moffitt Hospital, 13th Floor ∙ San Francisco, Ca 94143
Phone: (866) 246-4253 ∙ Fax: (415) 502-7814